Myasthenia gravis in the elderly - Is it different?

被引:99
|
作者
Aarli, Johan A. [1 ]
机构
[1] Univ Bergen, Dept Neurol, N-5014 Bergen, Norway
来源
MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE | 2008年 / 1132卷
关键词
myasthenia gravis; late onset; thymus; titin antibodies; thymectomy;
D O I
10.1196/annals.1405.040
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We have defined myasthenia gravis (MG) in the elderly as onset after the age of 50 years. MG is diagnosed more often today than previously. The increase is mainly found in patients over the age of 50 years. Neurologists therefore see more old patients with MG now than before. Prevalence of the early-onset form of MG seems to be unchanged. Recent data indicate that MG may still be substantially underdiagnosed in very old people. Ptosis, diplopia, weakness of the facial muscles, and problems of articulation are important clinical signs in MG and are easier to detect in a youthful appearance. Since ageing causes a decrease in the total eyelid area with sagging of the lower eyelids, a ptosis may be more difficult to diagnose in the elderly. In addition, diplopia may not be detected because of reduced vision due to macular degeneration or cataract formation. Ocular symptoms of MG are therefore more easily missed in the elderly. Thymomatous MG is more common among older patients than it is in younger onset. The mean age at onset of MG for thymoma cases is 50-60 years. Approximately 10-15% of all MG patients have a thymoma, and around 40% of all thymoma cases are associated with MG. During normal aging, the thymus tissue becomes atrophic and replaced with fat. Recent data on MG thymus pathology suggest that lymphocyte accumulation indicating residual thymus may also be found in the elderly, and that there is little qualitative difference between the young and the old thymus from MG patients. The mean concentration of antibodies to acetylcholine receptor (AChR) is lower in MG in the elderly than in early-onset or thymoma-associated MG. Seronegative MG is less common among older patients. Approximately 30% of patients with late-onset, nonthymoma MG have antibodies to titin, while such antibodies are extremely scarce in early-onset MG. Titin antibodies in MG patients seem to be associated with a higher frequency of DR7 antigen and a decrease of DR3 antigen. The antibody response in MG may therefore be influenced by the genetic background.
引用
收藏
页码:238 / 243
页数:6
相关论文
共 50 条
  • [21] LATE AND ELDERLY ONSET MYASTHENIA GRAVIS IN BULGARIAN POPULATION
    Vavrek, Evgenii
    Koleva, Natalia
    Alexandrov, Alexander S.
    Vassileva, Evgenia
    Muradyan, Naira
    Vavrek, Nely
    Daskalov, Marin
    COMPTES RENDUS DE L ACADEMIE BULGARE DES SCIENCES, 2014, 67 (07): : 1029 - 152
  • [22] DETERMINANTS OF COGNITIVE IMPAIRMENT IN ELDERLY MYASTHENIA GRAVIS PATIENTS
    Marra, Camillo
    Marsili, Francesca
    Quaranta, Davide
    Evoli, Amelia
    MUSCLE & NERVE, 2009, 40 (06) : 952 - 959
  • [23] Characteristics of myasthenia gravis in elderly patients: a retrospective study
    Li, Yi
    Dong, Xiaohua
    Li, Zhibin
    Peng, Yuyao
    Jin, Wanlin
    Zhou, Ran
    Jiang, Fei
    Xu, Liqun
    Luo, Zhaohui
    Yang, Huan
    NEUROLOGICAL SCIENCES, 2022, 43 (04) : 2775 - 2783
  • [24] Treatment of Myasthenia Gravis
    Vikas Kumar
    Henry J. Kaminski
    Current Neurology and Neuroscience Reports, 2011, 11 : 89 - 96
  • [25] Treatment of Myasthenia Gravis
    Kumar, Vikas
    Kaminski, Henry J.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (01) : 89 - 96
  • [26] Juvenile myasthenia gravis
    Papazian, Oscar
    Alfonso, Israel
    Araguez, Nayle
    MEDICINA-BUENOS AIRES, 2009, 69 (01) : 71 - 83
  • [27] Autoimmune myasthenia gravis
    Gilhus, Nils Erik
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (03) : 351 - 358
  • [28] Myasthenia gravis and thymoma
    De Assis, JL
    Zambon, AA
    Souza, PS
    Marchiori, PE
    ARQUIVOS DE NEURO-PSIQUIATRIA, 1999, 57 (01) : 6 - 13
  • [29] Ocular myasthenia gravis
    Pitz, S.
    Jordan, B.
    Zierz, S.
    OPHTHALMOLOGE, 2013, 110 (05): : 471 - 480
  • [30] Management of myasthenia gravis
    Saperstein, DS
    Barohn, RJ
    SEMINARS IN NEUROLOGY, 2004, 24 (01) : 41 - 48